OKYO News and Press, OKYO Pharma Limited From 09/22/25

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pa...

2025-08-12 16:15:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ. After dropping to a low o...

2025-08-11 18:45:12 ET OKYO Pharma Limited (OKYO) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 9.93%. The average open to low on the day of earnings was -4.00%. The average open to cl...

2025-08-11 18:40:13 ET OKYO Pharma Limited (OKYO) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in OKYO stock price following earnings has averaged ±6.74% , with a median of 6.49%. ...

LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pai...

2025-07-16 12:48:10 ET More on OKYO Pharma Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma Read the full article on Seeking Alpha For further details see: OKYO Pharm...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment. Urcosimod (0.05%) demonstrated a marked reduction in p...

Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research update on OKYO Pharma Limite...

LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory...

LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye d...